Home
About Us
FAQ
Contact Us
Media Tools
ExpertConnect App
MyExpertNet
University Partners
Becoming a Partner
Key Organizations
Search Assistance
Help
Expert Profile
Views:
50
Share
QR code
Edit Profile
Giuseppe Morelli
Clinical Professor
MD-GASTROENTERLOGY-LIVER | COLLEGE-MEDICINE
View:
Select
All (all in one)
Research Terms and Keywords
Publications
Co-Investigator Network
Websites
Contact
All
Research
Publications
Network
Websites
Contact
Research Terms & Keywords
Research Terms
Medical Sciences
Industries
Health Care
Research Projects
Ends
Title
06-2025
HCV-TARGET ADMIN CORE
HCV-TARGET ADMIN CORE
03-2022
Prioritize Study
Prioritize Study
10-2018
A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks....
A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks....
09-2018
A Phase 3, Global, Multicenter, Randomized, double blind placebo controlled study to investigate the safety and efficacy of sofosbuvir/velpatasvir/GS-9857 fixed dose combination for 12 weeks in direct acting antiviral-experienced
A Phase 3, Global, Multicenter, Randomized, double blind placebo controlled study to investigate the safety and efficacy of sofosbuvir/velpatasvir/GS-9857 fixed dose combination for 12 weeks in direct acting antiviral-experienced
08-2018
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients with NASH Cirrhosis
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients with NASH Cirrhosis
06-2018
Open-Label Study to Evaluate the Safety and Efficacy of the Combination of Ombitasvir
Open-Label Study to Evaluate the Safety and Efficacy of the Combination of Ombitasvir
04-2018
Clinical evaluation of the Xpert HCV VL.Assay
Clinical evaluation of the Xpert HCV VL.Assay
12-2017
Immuron "A phase II, randomized, doduble-blind, placebo-controlled study of IMM-124E for patients with non-alcoholic steatohepatitis"
Immuron "A phase II, randomized, doduble-blind, placebo-controlled study of IMM-124E for patients with non-alcoholic steatohepatitis"
11-2017
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection
10-2017
A Randomized, Open Label Study to Evaluate The Efficacy And Safety Of Sofosbuvir/GS-5816 Fixed Dose Combination With Ribavirin For 24 Weeks In Chronic HCV Infected Subjects Who Participated In A Prior Gilead Sponsored HCV Treatment Study"
A Randomized, Open Label Study to Evaluate The Efficacy And Safety Of Sofosbuvir/GS-5816 Fixed Dose Combination With Ribavirin For 24 Weeks In Chronic HCV Infected Subjects Who Participated In A Prior Gilead Sponsored HCV Treatment Study"
09-2017
M11-652 'A Rand., Open-Label, Study Antiviral Activity, Safety, and PK, of ABT-450 w/ Ritonavir (ABT-450/r) in Combo with ABT-267 and/or ABT-333 W&W/O (RBV) for 8, 12 or 24 Weeks in Na?ve and Null Responder Subjects with Genotype 1 HCV
M11-652 'A Rand., Open-Label, Study Antiviral Activity, Safety, and PK, of ABT-450 w/ Ritonavir (ABT-450/r) in Combo with ABT-267 and/or ABT-333 W&W/O (RBV) for 8, 12 or 24 Weeks in Na?ve and Null Responder Subjects with Genotype 1 HCV
08-2017
Gilead GS-US-342-1139" A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 FDC for 12 Wks with Sofos and RBV for 12 Wks in Subjects with Chronic Genotype 2 HCV Infection
Gilead GS-US-342-1139" A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 FDC for 12 Wks with Sofos and RBV for 12 Wks in Subjects with Chronic Genotype 2 HCV Infection
08-2017
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir with or without Ribavarin (RBV) in Treatment-Na?ve Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir with or without Ribavarin (RBV) in Treatment-Na?ve Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
08-2017
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects with Liver Cirrhosis
A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects with Liver Cirrhosis
07-2017
Gilead GS-US-342-1138" A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV"
Gilead GS-US-342-1138" A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV"
06-2017
'Parallel-Open-Label, Rand Study to Eval. Safety, Pharmacokinetics and Pharmacodynamics of PSI-7977 in Combination with BMS-790052 with or without Ribavirin in Treatment-Naive Subjects Chronically Infected with Hepatitis C Virus Genotypes 1, 2 OR 3
'Parallel-Open-Label, Rand Study to Eval. Safety, Pharmacokinetics and Pharmacodynamics of PSI-7977 in Combination with BMS-790052 with or without Ribavirin in Treatment-Naive Subjects Chronically Infected with Hepatitis C Virus Genotypes 1, 2 OR 3
06-2017
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects with Chronic Genotype 3 HCV Infection"
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects with Chronic Genotype 3 HCV Infection"
11-2016
'Open-Label, Study to Evaluate Eff and Safety of Sofosbuvir/Ledipasvir FDC + RBV for 12 Wks in Chronic Geno 1 HCV Subjects Who Participated in Prior Gilead-Sponsored HCV Tx study'
'Open-Label, Study to Evaluate Eff and Safety of Sofosbuvir/Ledipasvir FDC + RBV for 12 Wks in Chronic Geno 1 HCV Subjects Who Participated in Prior Gilead-Sponsored HCV Tx study'
08-2016
BMSAI444010 'A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa02a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection'
BMSAI444010 'A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa02a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection'
08-2016
RNLC2131 A RAND, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE SOLID DISPERSION (SSD) TABLETS FOR THE PREV OF COMPLICATIONS IN SUBJECTS WITH EARLY DECOMP LIVER CIRRHOSIS
RNLC2131 A RAND, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE SOLID DISPERSION (SSD) TABLETS FOR THE PREV OF COMPLICATIONS IN SUBJECTS WITH EARLY DECOMP LIVER CIRRHOSIS
08-2016
Gilead 367-1170 'A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks..
Gilead 367-1170 'A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks..
04-2016
GS-US-342-0109 'A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment Experienced Subjects with Chronic HCV Infection'
GS-US-342-0109 'A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment Experienced Subjects with Chronic HCV Infection'
04-2016
GS-US-342-0102 'A PHASE 2, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT-NAIVE SUBJECTS WITH CHRONIC HCV INFECTION'
GS-US-342-0102 'A PHASE 2, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT-NAIVE SUBJECTS WITH CHRONIC HCV INFECTION'
03-2016
VX09-222-103 'A Randomized, Parallel-Group, Dose-Ranging Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Antiviral Activity of VX-222 and Telaprevir in Combination With and Without Peginterferon-Alfa-2a (Pegasys) and Ribavirin (Copegus) in Trea
VX09-222-103 'A Randomized, Parallel-Group, Dose-Ranging Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Antiviral Activity of VX-222 and Telaprevir in Combination With and Without Peginterferon-Alfa-2a (Pegasys) and Ribavirin (Copegus) in Trea
03-2016
An Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ABT-450 with Ritonavir (ABT-450/R) in Combination with ABT-267 With and Without ABT-333 and/or Ribavirin (RBV) in Treatment Naive Adults with Genotype 1 CHC
An Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ABT-450 with Ritonavir (ABT-450/R) in Combination with ABT-267 With and Without ABT-333 and/or Ribavirin (RBV) in Treatment Naive Adults with Genotype 1 CHC
12-2015
RFHE4044 'A MULTICENTER,RANDOMIZED,OPEN-LABEL, ACTIVE-CONTROLLED,TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF RIFAXIMIN 550MG WITH AND WITHOUT LACTULOSE IN SUBJECTS WITH A HISTORY OF RECURRENT OVERT HE'
RFHE4044 'A MULTICENTER,RANDOMIZED,OPEN-LABEL, ACTIVE-CONTROLLED,TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF RIFAXIMIN 550MG WITH AND WITHOUT LACTULOSE IN SUBJECTS WITH A HISTORY OF RECURRENT OVERT HE'
09-2015
Hyperion HPN-100-022 "AN OBSERVATIONAL STUDY TO ASSESS DOCUMENTATION OF HEPATIC ENCEPHALOPATHY IN CLINICAL PRACTICE"
Hyperion HPN-100-022 "AN OBSERVATIONAL STUDY TO ASSESS DOCUMENTATION OF HEPATIC ENCEPHALOPATHY IN CLINICAL PRACTICE"
06-2015
TVR + SOF-CCC
TVR + SOF-CCC
06-2015
156-IST-10-06 Tolvaptan in Cirrhotic Ascites Patients
156-IST-10-06 Tolvaptan in Cirrhotic Ascites Patients
03-2015
HCV-TARGET FUNDING SOURCE: Genentech
HCV-TARGET FUNDING SOURCE: Genentech
03-2015
PROTOCOLS GS-US-334-0107, 0108, 0109, and 0110
PROTOCOLS GS-US-334-0107, 0108, 0109, and 0110
10-2014
P2938-0721 QUANTUM
P2938-0721 QUANTUM
08-2014
GS-US-256-0124
GS-US-256-0124
04-2014
P7977-0724 ATOMIC
P7977-0724 ATOMIC
03-2014
An Open-Label Pilot Study to Evaluate the Antiviral Acti
An Open-Label Pilot Study to Evaluate the Antiviral Acti
02-2013
P7977-0422P7977-0422 A Multi-Center, Placebo-Controlled
P7977-0422P7977-0422 A Multi-Center, Placebo-Controlled
09-2012
Zymo 526H04
Zymo 526H04
06-2012
GS-US-196-0140
GS-US-196-0140
04-2012
GSK TPL 103922
GSK TPL 103922
04-2012
FISSION: P7977-1231
FISSION: P7977-1231
04-2011
Ocera AST-MHE 201
Ocera AST-MHE 201
09-2010
EFC10143
EFC10143
09-2010
EFC4492 CATS
EFC4492 CATS
08-2010
SPAR EFC 4493 - Satavaptan in the Prevention of Ascites
SPAR EFC 4493 - Satavaptan in the Prevention of Ascites
03-2010
Strong 2-EFC10144
Strong 2-EFC10144
01-2010
IRHC-002
IRHC-002
01-2009
ML18124
ML18124
01-2008
A PHASE 3, RNDMZD, OPN-LBL STUDY OF THE SAFETY AND EFFIC
A PHASE 3, RNDMZD, OPN-LBL STUDY OF THE SAFETY AND EFFIC
Publications
Search Google Scholar for Giuseppe Morelli
Co-Investigator Network
Virginia Clark
Program Director & Associate Professor
University of Florida
MD-GASTROENTERLOGY-LIVER, College-Medicine
clarkvc@medicine.ufl.edu
Roberto Firpi-Morell
Professor
University of Florida
MD-GASTROENTERLOGY-LIVER, College-Medicine
roberto.firpi@medicine.ufl.edu
Maged Ghali
Professor; Chief, Division of Gastroenterology; Program Director, Gastroenterology Fellowship
University of Florida
JX-MEDICINE AT JAX, College-Medicine Jacksonville
maged.ghali@jax.ufl.edu
Inactive Expert
Miguel Malespin
University of Florida
MD-GASTROENTERLOGY-LIVER, College-Medicine
miguel.malespin@jax.ufl.edu
Keith Muller
Professor
University of Florida
MD-HOBI-GENERAL, College-Medicine
kmuller@ufl.edu
David Nelson
Senior Vice President for Health Affairs, UF & President, UF Health
University of Florida
HA-EXECUTIVE, Office Of Health Affairs
nelsodr@ufl.edu
Inactive Expert
Peggy Parnell
Program Assistant
University of Florida
MD-GASTROENTERLOGY-LIVER, College-Medicine
-
Websites
Search Google Scholar for Giuseppe Morelli
Contact Information
morelgj@medicine.ufl.edu
3522739500
2004 MOWRY RD GAINESVILLE, FL 32610-3010
Profile QR code
What is this?
Keyword Search
Please enter valid search criteria.
Search
Centers
Experts
Projects
Speakers
Stories
Technologies
Videos
University
All Universities
Florida A&M University
Florida Atlantic University
Florida Gulf Coast University
Florida Institute of Technology
Florida International University
Florida State University
University of Central Florida
University of Florida
University of Miami
University of North Florida
University of South Florida
University of West Florida
Browse by STEM
Biotechnology
Computer Science
Energy
Engineering
Environmental Sciences
Information Science
Life Sciences
Mathematics
Medical Sciences
Military Sciences
Natural Sciences
Physical Sciences
Plant Sciences
Science
Space Sciences
Technology
Transportation
